Zoledronic Acid Administration in Acute Spinal Cord Injury

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).
Epistemonikos ID: d43e27861745ce2b202dbb089b98f3a39d936309
First added on: May 11, 2024